Evaluate the safety, tolerability, and immunogenicity of adjuvanted preventive dual AΒ/TAU vaccine, duvax in healthy volunteers

Active Grant Awarded Last action

Award ID
R44AG091903
Recipient
Awarding agency
Obligated
$1,757,036

Award facts

Assistance listing
93.866 Aging Research
Completion date 54% complete
Originally
Place of performance
Irvine, CA 92617, USA

Award details come from USAspending.gov.

Description

Abstract
Alzheimer's disease (ad) represents the most prevalent form of dementia, characterized by memory impairment and changes in multiple cognitive functions. This complex condition arises from a blend of genetic and environmental influences, culminating in hallmark pathologies like Β-amyloid (AΒ) oligomers/fibrils/plaques and TAU aggregates/tangles, followed by inflammation and severe neurodegeneration. The modern amyloid cascade hypothesis emphasizes the pivotal role of AΒ oligomers in initiating TAU pathology and subsequent inflammatory responses, oxidative stress, and synaptic and neuronal loss, while the accumulation of pathological TAU is directly correlated with the disease progression and severity. Therefore, the development of potential therapies for ad has been mainly focused on reducing pathological AΒ or TAU and, more recently, on inflammation associated with accumulating these pathological molecules in the brain. Increasing evidence underscores the synergistic pathogenic interaction between AΒ and TAU, sparking interest in therapies concurrently addressing both. Scientists from the institute for molecular medicine (IMM) advocate for an immunogenic dual vaccine targeting both AΒ and TAU pathologies, deeming IT optimal for inhibiting AΒ aggregation, reducing TAU accumulation, and potentially delaying clinical ad onset. This vision led to the creation of duvax, an adjuvanted (ADAXCPG), multitep vaccine platform-based dual vaccine, demonstrating promising immunogenicity and efficacy in rigorous ad mouse models. They finalized all FDA-required IND-enabling studies, including: (I) manufacturing of cgmp recombinant protein (drug product) with CMC information; (II) safety/toxicology studies of duvax in disease model of TG mice. Nuravax, INC., having licensed duvax, collaborates with IMM and proposes in phase 1 of this program (R43) to define the safe and immunogenic optimal dose range of duvax in non-human primates, concurrently preparing and submitting the IND30496 application to the FDA for phase 1 safety and immunogenicity trials in healthy human subjects. Transitioning into phase 2 (R44), nuravax plans a randomized, double-blind, placebo-controlled study to evaluate duvax's safety/tolerability and immunogenicity in male and female healthy volunteers aged 40-65 years. Completion of this comprehensive study will provide essential data supporting future phase 2 trials tailored for age-matched preclinical ad populations, advancing our comprehension and potential treatment avenues for this debilitating condition.

Transactions

Action Obligated Date
Amendment $1,257,282
Amendment $0
Original award $499,754

Subawards

Subrecipient Amount Awarded
Institute For Molecular Medicine Inc. Subawardee is responsible for immunological studies, such as the detection of antibody responses against Aβ and Tau, as well as Th cell responses. Oversee… $130,000

Quick answers

Who received award R44AG091903?

R44AG091903 was awarded to Nuravax, Inc. by National Institute on Aging (National Institutes of Health) on March 25, 2025.

How much is award R44AG091903 worth?

$1,757,036 has been obligated on R44AG091903.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award